BOSTON—Exosome Diagnostics Inc. and Intezyne Inc. have teamed up in a collaboration agreement aimed at designing and validating a highly sensitive exosomal RNA-based assay for use in Intezyne’s Phase 1/2 clinical trials of IT-139. The assay will make use of Exosome Diagnostics’ ExoLution isolation kit and will support patient stratification and long-term monitoring. IT-139 is a novel cancer resistance pathway inhibitor for pancreatic, gastric and other cancers in combination with current anticancer therapies.

 

“As we delve further into the novel mechanism of action of IT-139, we needed a companion diagnostic assay that could reliably measure IT-139’s impact on GRP78 levels,” stated Suzanne Bakewell, Intezyne’s vice president of preclinical development. “Exosome’s cutting-edge technology has demonstrated the potential to increase the clinical utility of other products, and we are excited to collaborate with Exosome to develop a potentially groundbreaking companion diagnostic to predict treatment outcome for IT-139.”